The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases

Wannee Kantasiripitak(Certara (United States)), Erwin Dreesen(KU Leuven), Séverine Vermeire(KU Leuven), Marc Ferrante(Universitair Ziekenhuis Leuven), Dahham Alsoud(KU Leuven), Bram Verstockt(Universitair Ziekenhuis Leuven), Triana Lobatón, Ann Gils(KU Leuven), Debby Thomas(KU Leuven)

British Journal of Clinical Pharmacology

February 19, 2021

10.1111/bcp.14785

Cited by 14

Related Papers

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease

|Nature Genetics|2008|2.6k

A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis

|Gut|2013|1.9k

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications

|Journal of Crohn s and Colitis|2018|1.8k

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

|New England Journal of Medicine|2016|1.8k

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment

|Journal of Crohn s and Colitis|2019|1.4k